Check out the following webinar where Drs. Heymach, MD and Reuben, PhD discuss the latest research on RET driven cancers.
While research is ongoing, RET cancers aren't typically thought to be responsive to available immune checkpoint inhibitors. Given the success of immune treatments in other cancers, there remains an unmet need for an immune treatment approach in the RET community. Dr. Reuben discusses a possible immune approach that his lab is studying that could lead to treatments for RET fusion positive cancers using T cell receptors.
Dr. Heymach research focuses on trying to determine the most common resistance mechanisms to existing RET inhibitors. His lab is also looking into ways in which certain RET mutations might respond better or worse to different treatments. The goals of this work will hopefully help determine new treatments to target resistance to existing RET inhibitors and best treatment strategies prior to developing resistance.